JP2004529893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529893A5 JP2004529893A5 JP2002569239A JP2002569239A JP2004529893A5 JP 2004529893 A5 JP2004529893 A5 JP 2004529893A5 JP 2002569239 A JP2002569239 A JP 2002569239A JP 2002569239 A JP2002569239 A JP 2002569239A JP 2004529893 A5 JP2004529893 A5 JP 2004529893A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- eletriptan
- measured
- absence
- oral bioavailability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 27
- 230000002401 inhibitory effect Effects 0.000 claims 27
- OTLDLQZJRFYOJR-LJQANCHMSA-N Eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 claims 19
- 229960002472 eletriptan Drugs 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 16
- 230000035536 Oral bioavailability Effects 0.000 claims 14
- 230000036220 oral bioavailability Effects 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 230000035533 AUC Effects 0.000 claims 8
- 230000037242 Cmax Effects 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims 4
- 206010027599 Migraine Diseases 0.000 claims 4
- 208000008085 Migraine Disorders Diseases 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 229960004503 metoclopramide Drugs 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 210000002966 Serum Anatomy 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0105131.7A GB0105131D0 (en) | 2001-03-01 | 2001-03-01 | Compositions having improved bioavailability |
| PCT/IB2002/000512 WO2002070070A2 (en) | 2001-03-01 | 2002-02-20 | Compositions having improved bioavailability of eletriptan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004529893A JP2004529893A (ja) | 2004-09-30 |
| JP2004529893A5 true JP2004529893A5 (es) | 2005-05-26 |
Family
ID=9909814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002569239A Pending JP2004529893A (ja) | 2001-03-01 | 2002-02-20 | 改善されたバイオアベイラビリティーを有する組成物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1372785A2 (es) |
| JP (1) | JP2004529893A (es) |
| AU (1) | AU2002232061A1 (es) |
| BR (1) | BR0207751A (es) |
| CA (1) | CA2439917A1 (es) |
| GB (1) | GB0105131D0 (es) |
| MX (1) | MXPA03007836A (es) |
| WO (1) | WO2002070070A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006522790A (ja) * | 2003-04-11 | 2006-10-05 | ファイザー・インク | エレトリプタンと重炭酸ナトリウムを含む医薬組み合わせ物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9709739D0 (en) * | 1997-05-14 | 1997-07-02 | Merck Sharp & Dohme | Pharmaceutical formulation |
| US6255334B1 (en) * | 1998-10-30 | 2001-07-03 | Pfizer Inc | 5HT 1 receptor agonists and metoclopramide for the treatment of migraine |
-
2001
- 2001-03-01 GB GBGB0105131.7A patent/GB0105131D0/en not_active Ceased
-
2002
- 2002-02-20 WO PCT/IB2002/000512 patent/WO2002070070A2/en not_active Application Discontinuation
- 2002-02-20 EP EP02712162A patent/EP1372785A2/en not_active Withdrawn
- 2002-02-20 JP JP2002569239A patent/JP2004529893A/ja active Pending
- 2002-02-20 BR BR0207751-5A patent/BR0207751A/pt not_active IP Right Cessation
- 2002-02-20 AU AU2002232061A patent/AU2002232061A1/en not_active Abandoned
- 2002-02-20 MX MXPA03007836A patent/MXPA03007836A/es unknown
- 2002-02-20 CA CA002439917A patent/CA2439917A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| JP2006504795A5 (es) | ||
| JP2022180461A5 (es) | ||
| JP2014515373A5 (es) | ||
| JP2005515966A5 (es) | ||
| JP2015526458A5 (es) | ||
| SE9804314D0 (sv) | New pharmaceutical formulation | |
| JP2007515469A5 (es) | ||
| JP2004519469A5 (es) | ||
| JP2009536147A5 (es) | ||
| AR048431A1 (es) | Formulaciones galenicas de compuestos organicos | |
| JP2007532607A5 (es) | ||
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| RU2008102911A (ru) | Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы | |
| JP2002528502A5 (es) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2006514092A5 (es) | ||
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| SE9901573D0 (sv) | New compounds | |
| JP2003519228A5 (es) | ||
| JP2006518731A5 (es) | ||
| JP2006515299A5 (es) | ||
| RU2002122084A (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств | |
| JP2011500589A5 (es) | ||
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи |